Aquinox Pharmaceuticals Closes US$25M Series B Financing

Aquinox Pharmaceuticals Inc., a Vancouver, BC, Canada-based biopharmaceutical company that develops innovative small molecule therapeutics for the treatment of inflammatory disease and cancer, has closed a US$25m Series B financing.
The rounds was led by Ventures West Capital, with participation from new investor Pfizer Venture Investments (PVI) and existing partners Johnson & Johnson Development Corporation, Baker Brothers Investments and BC Advantage Funds (VCC) Ltd.
The new capital will allow the company to advance its lead clinical candidate from its SH2-containing inositol-5′-phosphatase (“SHIP1”) agonist program, AQX-1125, into Phase I and Phase II clinical studies. Aquinox will also continue drug discovery efforts towards the nomination of a second clinical candidate and additional pipeline candidates from its SHIP1 program.

Join the discussion